Xeris Biopharma Holdings, Inc. Banner Image

Xeris Biopharma Holdings, Inc.

  • Ticker XERS
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Xeris Biopharma Holdings, Inc. Logo Image
  • 51-200 Employees
  • Based in Chicago, Illinois
Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis®, a proven therapy for primary periodic paralysis, and RecorlevMore® for the treatment of endogenous Cushing’s syndrome. Xeris also has a robust pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms, XeriSol™ and XeriJect™, supporting long-term product development and commercial success.
4.8 / 5.0 (121)

Xeris Biopharma Holdings, Inc. reports have an aggregate usefulness score of 4.8 based on 121 reviews.

Xeris Biopharma Holdings, Inc.

Most Recent Annual Report

Xeris Biopharma Holdings, Inc.
MOST RECENT 2023 Annual Report and Form 10K

Older/Archived Annual Reports

Xeris Biopharma Holdings, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!